Compound Information | SONAR Target prediction | Name: | Mevastatin | Unique Identifier: | LOPAC 01035 | MolClass: | Checkout models in ver1.5 and ver1.0 | Molecular Formula: | C23H34O5 | Molecular Weight: | 360.275 g/mol | X log p: | 5.569 (online calculus) | Lipinksi Failures | 1 | TPSA | 52.6 | Hydrogen Bond Donor Count: | 0 | Hydrogen Bond Acceptors Count: | 5 | Rotatable Bond Count: | 7 | Canonical Smiles: | CCC(C)C(=O)OC1CCC=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C12 | Class: | Antibiotic | Action: | Inhibitor | Selectivity: | Ras, Rho | Generic_name: | Simvastatin | Chemical_iupac_name: | [8-[2-(4-hydroxy-6-oxo-tetrahydropyran-2-yl)ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahyd ronaphthalen-1-yl]2,2-dimethylbutanoate | Drug_type: | Approved Drug | Pharmgkb_id: | PA451363 | Kegg_compound_id: | D00434 | Drugbank_id: | APRD00104 | Melting_point: | 135-138oC | H2o_solubility: | 0.76 mg/L | Logp: | 4.937 | Cas_registry_number: | 79902-63-9 | Drug_category: | Antilipemic Agents; Anticholesteremic Agents; HMG-CoA Reductase Inhibitors; ATC:C10AA01 | Indication: | For the treatment of hypercholesterolemia. | Pharmacology: | Simvastatin, the methylated form of lovastatin, is an oral antilipemic agent which inhibits HMG-CoA reductase. simvastatin is used in the treatment of primary hypercholesterolemia and is effective in reducing total and LDL-cholesterol as well as plasma triglycerides and apolipoprotein B. | Mechanism_of_action: | The 6-membered lactone ring of simvastatin is hydrolyzed in vivo to generate mevinolinic acid, an active metabolite structurally similar to HMG-CoA (hydroxymethylglutaryl CoA). Once hydrolyzed, simvastatin competes with HMG-CoA for HMG-CoA reductase, a hepatic microsomal enzyme. Interference with the activity of this enzyme reduces the quantity of mevalonic acid, a precursor of cholesterol. | Organisms_affected: | Humans and other mammals |
Species: |
4932 |
Condition: |
PAC10 |
Replicates: |
2 |
Raw OD Value: r im |
0.7532±0.00247487 |
Normalized OD Score: sc h |
1.0055±0.0000376763 |
Z-Score: |
0.2496±0.00145412 |
p-Value: |
0.802882 |
Z-Factor: |
-4.17206 |
Fitness Defect: |
0.2195 |
Bioactivity Statement: |
Nonactive |
Experimental Conditions | | Library: | Lopac | Plate Number and Position: | 10|D5 | Drug Concentration: | 50.00 nM | OD Absorbance: | 600 nm | Robot Temperature: | 27.60 Celcius | Date: | 2005-04-15 YYYY-MM-DD | Plate CH Control (+): | 0.04575±0.00087 | Plate DMSO Control (-): | 0.705125±0.01540 | Plate Z-Factor: | 0.9239 |
| png ps pdf |
16038314 |
sodium (2R,4R)-2-[2-[(1S,2R,6R,8S,8aS)-8-(2,2-dimethylbutanoyloxy)-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthale n-1-yl]ethyl]-6-oxo-oxan-4-olate |
internal high similarity DBLink | Rows returned: 3 | |
active | Cluster 2780 | Additional Members: 9 | Rows returned: 6 | |
|